Modeling sustained treatment effects in tumor xenograft experiments.

Abstract:

:In cancer drug development, demonstrated efficacy in tumor xenograft models is an important step toward bringing a promising compound to human use. A key outcome variable is tumor volume measured over a period of time, while mice are treated with certain treatment regimens. A constrained parametric model has been proposed to account for special features, such as intrinsic tumor growth, or tumor volume truncations due to tumor size being either too large or too small to detect. However, since the drug concentration in the blood of a mouse or its tissues may be stabilized at a certain level and maintained during a period of time, the treatment may have sustained effects. This article extends the constrained parametric model to account for the sustained drug effects. The ECM algorithm for incomplete data is applied to estimating the dose-response relationship in the proposed model. The model selection based on likelihood functions is given and a simulation study is conducted to investigate the performance of the proposed estimator. A real xenograft study on the antitumor agent temozolomide combined with irinotecan against the rhabdomyosarcoma is analyzed using the proposed methods.

journal_name

J Biopharm Stat

authors

Fang HB,Deng D,Zhang T,Tan M

doi

10.1080/10543406.2014.901340

subject

Has Abstract

pub_date

2014-01-01 00:00:00

pages

755-67

issue

4

eissn

1054-3406

issn

1520-5711

journal_volume

24

pub_type

杂志文章
  • Simultaneous confidence interval methods for analytical similarity assessment.

    abstract::In analytical similarity assessment of a biosimilar product, key quality attributes of the test and reference products need to be shown statistically similar. When there were multiple references, similarity among the reference products is also required. We proposed a simultaneous confidence approach based on the fiduc...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2019.1657142

    authors: Zheng J,Yin D,Yuan M,Chow SC

    更新日期:2019-01-01 00:00:00

  • Bayesian optimal designs for pharmacokinetic models: sensitivity to uncertainty.

    abstract::We studied the sensitivity of the number of unique design points and their placement, in Bayesian optimal designs for pharmacokinetic models, with respect to the magnitude of prior uncertainty. We used two and three-parameter pharmacokinetic models with fixed and mixed effects and two Bayesian optimal design criteria,...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400701514007

    authors: Dokoumetzidis A,Aarons L

    更新日期:2007-01-01 00:00:00

  • Statistical assessment of biosimilarity based on the relative distance between follow-on biologics for binary endpoints.

    abstract::A new three-arm parallel design was recently proposed to investigate the biosimilarity between a biological product and a reference product by using the relative distance. The purpose of this article is to extend their results to binary endpoints for three popular metrics: the risk difference, the log relative risk, a...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.979195

    authors: Shin W,Kang SH

    更新日期:2016-01-01 00:00:00

  • Sample size determination for testing equality in a cluster randomized trial with noncompliance.

    abstract::For administrative convenience or cost efficiency, we may often employ a cluster randomized trial (CRT), in which randomized units are clusters of patients rather than individual patients. Furthermore, because of ethical reasons or patient's decision, it is not uncommon to encounter data in which there are patients no...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400903350465

    authors: Lui KJ,Chang KC

    更新日期:2011-01-01 00:00:00

  • Statistical applications for in vitro diagnostic tests and other medical device clinical trials.

    abstract::Some statistical methods applied to in vitro diagnostic tests for the three primary indications (screening, diagnosis, and monitoring) are discussed. Various examples with practical statistical applications are presented, including test for k by k ordered categorical matched-pair data for screening of cervical cancer,...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409708835208

    authors: Lao CS

    更新日期:1997-11-01 00:00:00

  • Simultaneous use of weighted logrank and standardized Kaplan-Meier statistics.

    abstract::Rank-based test procedures in censored survival data differ considerably in their sensitivity to various alternatives to the hypothesis of equality of underlying distributions. Procedures based on the simultaneous use of multiple statistics provide an appealing approach to obtaining more global sensitivity while maint...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400500508952

    authors: Yang P,Fleming TR

    更新日期:2006-01-01 00:00:00

  • Designs for testing lack of fit for a nonlinear dose-response curve model.

    abstract::We would like to estimate the parameters of a dose-response function with the greatest precision as possible. For a two-parameter model, this is equivalent to minimizing the area of the confidence ellipsoid, i.e., a D-optimal design. Previous work on this particular model has included minimal designs. These designs ar...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-100101012

    authors: Lupinacci PJ,Raghavarao D

    更新日期:2000-02-01 00:00:00

  • A Bayesian approach for dose-escalation in a Phase I clinical trial incorporating pharmacodynamic endpoints.

    abstract::Bayesian decision procedures have already been proposed for and implemented in Phase I dose-escalation studies in healthy volunteers. The procedures have been based on pharmacokinetic responses reflecting the concentration of the drug in blood plasma and are conducted to learn about the dose-response relationship whil...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400701645165

    authors: Whitehead J,Zhou Y,Hampson L,Ledent E,Pereira A

    更新日期:2007-01-01 00:00:00

  • Simple methods for determination of the release limits for drug products.

    abstract::The potency of a batch of drug product needs to meet a release limits at the time of release so that the potency at the end of shelf life remains above the lower registration limit (LRL). This article discusses two methods which determine the release limits such that the chance to fail LRL at the end of shelf life of ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409808835225

    authors: Wei GC

    更新日期:1998-03-01 00:00:00

  • Determining a minimum clinically important difference between treatments for a patient-reported outcome.

    abstract::Patient-reported outcomes are important for assessing the effectiveness of treatments in many disease areas. For this reason, many new instruments that capture patient-reported outcomes have been developed over the past several decades. With the development of each new instrument, there is the ensuing question of what...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400903315757

    authors: Kirby S,Chuang-Stein C,Morris M

    更新日期:2010-09-01 00:00:00

  • Biomarker threshold adaptive designs for survival endpoints.

    abstract::Due to the importance of precision medicine, it is essential to identify the right patients for the right treatment. Biomarkers, which have been commonly used in clinical research as well as in clinical practice, can facilitate selection of patients with a good response to the treatment. In this paper, we describe a b...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2018.1434191

    authors: Diao G,Dong J,Zeng D,Ke C,Rong A,Ibrahim JG

    更新日期:2018-01-01 00:00:00

  • Permutation test following covariate-adaptive randomization in randomized controlled trials.

    abstract::In randomized controlled trials, patients are recruited and randomly allocated to treatments. Patients are never randomly sampled from large population of patients on treatments under study. Therefore, it is important to consider the design and statistical analysis based on the randomization model. In this article, we...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400802527908

    authors: Hasegawa T,Tango T

    更新日期:2009-01-01 00:00:00

  • Conditional and unconditional confidence intervals following a group sequential test.

    abstract::After a group sequential test, the naive confidence interval (CI) is usually biased in the sense that it does not cover the true parameter at the correct nominal level. Furthermore, when the stopping time is taken into account, the actual conditional confidence coverage probability can be much less accurate. In this a...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400500406595

    authors: Fan X,DeMets DL

    更新日期:2006-01-01 00:00:00

  • Sample size determination for Bayesian analysis of small n sequential, multiple assignment, randomized trials (snSMARTs) with three agents.

    abstract::The small n, Sequential, Multiple Assignment, Randomized Trial (snSMART) is a two-stage clinical trial design for rare diseases motivated by the comparison of three active treatments for isolated skin vasculitis in the ongoing clinical trial ARAMIS (a randomized multicenter study for isolated skin vasculitis, NCT09239...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2020.1815032

    authors: Wei B,Braun TM,Tamura RN,Kidwell K

    更新日期:2020-09-06 00:00:00

  • Bayesian approach to evaluation of bridging studies.

    abstract::We address the issue of analysis of clinical data generated by the bridging study conducted in the new region to evaluate the similarity for extrapolation of the foreign clinical data. A bridging study is usually conducted in the new region only after the test product is approved for commercial marketing in the origin...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/bip-120014568

    authors: Liu JP,Hsiao CF,Hsueh H

    更新日期:2002-08-01 00:00:00

  • Measuring parallelism, linearity, and relative potency in bioassay and immunoassay data.

    abstract::There is often a need to determine parallelism or linearity between pairs of dose-response data sets for various biological applications. This article describes a technique based on a modification of the well-known extra-sum-of-squares principle of statistical regression. The standard extra-sum-of-squares method uses ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-200056532

    authors: Gottschalk PG,Dunn JR

    更新日期:2005-01-01 00:00:00

  • Power approximation for the van Elteren test based on location-scale family of distributions.

    abstract::The van Elteren test, as a type of stratified Wilcoxon-Mann-Whitney test for comparing two treatments accounting for stratum effects, has been used to replace the analysis of variance when the normality assumption was seriously violated. The sample size estimation methods for the van Elteren test have been proposed an...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400600762939

    authors: Zhao YD,Qu Y,Rahardja D

    更新日期:2006-01-01 00:00:00

  • Estimating treatment effects in clinical crossover trials.

    abstract::Some current approaches to modeling crossover trials in two treatments are critically reviewed from the perspective of the practical requirements of the drug developer. Particular attention is paid to the AB/BA design, and the inadequacies of the once popular two-stage procedure are discussed in detail. The use of bas...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章,评审

    doi:10.1080/10543409808835233

    authors: Grieve A,Senn S

    更新日期:1998-05-01 00:00:00

  • Propensity score-integrated composite likelihood approach for augmenting the control arm of a randomized controlled trial by incorporating real-world data.

    abstract::In this paper, a propensity score-integrated composite likelihood (PSCL) approach is developed for cases in which the control arm of a two-arm randomized controlled trial (RCT) (treated vs control) is augmented with patients from real-world data (RWD) containing both clinical outcomes and covariates at the patient-lev...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2020.1730877

    authors: Chen WC,Wang C,Li H,Lu N,Tiwari R,Xu Y,Yue LQ

    更新日期:2020-05-03 00:00:00

  • Data-driven analysis strategies for proportion studies in adaptive group sequential test designs.

    abstract::Using multistage adaptive group sequential test designs, the investigator may perform data-driven changes in the design during the course of the trial without inflation of the Type I error rate. This is possible, for example, through the use of the inverse normal method of combining the p-values from the separate stag...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-120024196

    authors: Wassmer G

    更新日期:2003-11-01 00:00:00

  • Generalized estimating equations for multivariate response with the variates having different distributions.

    abstract::This paper addresses the problem of analyzing multivariate response with the variates having different distributions. We use the generalized estimating equations proposed by Prentice and Zhao (1) to estimate mean and covariance parameters. Wald statistics are used to test hypotheses about the parameters. Data from a t...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409608835129

    authors: May WL,Johnson WD

    更新日期:1996-05-01 00:00:00

  • Bayesian approach for cure models with a change-point based on covariate threshold: application to breast cancer data.

    abstract::In this study, a Bayesian approach was suggested to estimate a change-point according to a covariate threshold when some patients never experienced the event of interest. Gibbs sampler algorithm with latent binary cure indicators was used to simplify the implementation of Markov chain Monte Carlo method. Then, the acc...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2019.1632877

    authors: Shamsi F,Baghestani AR,Binesh F

    更新日期:2020-03-01 00:00:00

  • Balancing statistical and ethical considerations in planning clinical trials: recommendations for response-adaptive randomization urn designs.

    abstract::During a clinical trial, balancing statistical and ethical considerations are important. Response-adaptive randomization methods use the information from past patients to increase the probability of the next patient receiving the better treatment while avoiding the statistical concern of selection bias. We compared th...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2018.1437172

    authors: Piccorelli AV,Fraker SA

    更新日期:2018-01-01 00:00:00

  • Mixed-effects varying-coefficient model with skewed distribution coupled with cause-specific varying-coefficient hazard model with random-effects for longitudinal-competing risks data analysis.

    abstract::It is well known that there is strong relationship between HIV viral load and CD4 cell counts in AIDS studies. However, the relationship between them changes during the course of treatment and may vary among individuals. During treatments, some individuals may experience terminal events such as death. Because the term...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2015.1052493

    authors: Lu T,Wang M,Liu G,Dong GH,Qian F

    更新日期:2016-01-01 00:00:00

  • Design effects for highly clustered count data with varying length of follow-up--applying to the analysis of ICD shocks.

    abstract::Highly clustered count data are commonly seen in medical device clinical studies such as cardiac rhythm management. For instance, anti-arrhythmia shocks delivered from an implantable cardioverter-defibrillator (ICD) often occur as "storms", i.e., multiple shocks within a short period of time. There are unique challeng...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400701668241

    authors: Wang ZJ

    更新日期:2008-01-01 00:00:00

  • Dropouts in longitudinal studies: definitions and models.

    abstract::The widely used distinction of Little and Rubin (1) about types of randomness for missing data presents difficulties in its application to dropouts in longitudinal repeated measurement studies. In its place, a new typology of randomness for dropouts is proposed that relies on using a survival model for the dropout pro...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-100101981

    authors: Lindsey JK

    更新日期:2000-11-01 00:00:00

  • Bayesian assessment of the influence and interaction conditions in multipopulation tailoring clinical trials.

    abstract::Multipopulation tailoring trials provide a trial design option that supports the realization of tailored therapeutics or personalized medicine. Several recent publications have focused on statistical and clinical considerations that arise in these trials that are designed to study the overall treatment effect in a pop...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章,评审

    doi:10.1080/10543406.2013.856025

    authors: Millen BA,Dmitrienko A,Song G

    更新日期:2014-01-01 00:00:00

  • Interval estimation of the proportion ratio in repeated binary measurements under a stratified randomized clinical trial with noncompliance.

    abstract::The proportion ratio (PR) of a positive response between an experimental treatment and a standard treatment (or placebo) is often used to measure the relative treatment efficacy in a randomized clinical trial (RCT). For ethical reasons, it is almost inevitable to encounter some patients not complying with their assign...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2010.508139

    authors: Lui KJ,Chang KC

    更新日期:2012-01-01 00:00:00

  • Ratio of means vs. difference of means as measures of superiority, noninferiority, and average bioequivalence.

    abstract::Ratio of means (ROM) and difference of means (DOM) are often used in a superiority, noninferiority (NI), or average bioequivalence (ABE) test to evaluate whether the test mean is superior, NI, or equivalent to the reference (placebo or active control) mean. The literature provides recommendations regarding how to choo...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2016.1265536

    authors: Sun W,Grosser S,Tsong Y

    更新日期:2017-01-01 00:00:00

  • Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects.

    abstract::Noninferiority multiregional clinical trials (MRCTs) have recently received increasing attention in drug development. While a major goal in an MRCT is to estimate the global treatment effect, it is also important to assess the consistency of treatment effects across multiple regions. In this paper, we propose an intui...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2017.1293075

    authors: Diao G,Zeng D,Ibrahim JG,Rong A,Lee O,Zhang K,Chen Q

    更新日期:2017-01-01 00:00:00